Immunization with ICs induces anti-tumor immunity in Irf8 Δ32 mice. (A) WT and Δ32 mice intravenously immunized with CpG + anti-CD40 antibody and either 5 μg of sOVA or OVA-IC. After 5 days, 10⁶ 1956-mOVA was implanted subcutaneously, and tumor clearance was measured until day 15. Data are pooled biologically independent samples from three independent experiments. (B) cDCs were evaluated in spleen and tumor draining LN in WT or Δ32 mice with the indicated conditions of immunization and tumor implantation. Two-color histograms are pregated as B220⁻ CD11c⁺ MHC-II⁺ cells. Shown are two-color histograms for XCR1 and CD172 expression. Numbers are the percentage of cells in the indicated gates. (C)Δ32 mice treated with i.p. PBS or i.p. anti-CD8β antibody to deplete CD8⁺ T cells. Next day, mice were subcutaneously immunized with CFA and either 5 μg of sOVA or OVA-IC. After 5 days, mice were subcutaneously implanted with 10⁶ 1956-mOVA cells and tumor growth monitored for 15 days. (Left) tumor growth. Data are represented as mean values ± SD of pooled biologically independent samples from two independent experiments (n = 6 for each genotype). Two-way ANOVA with Tukey’s multiple comparisons test. ns = not significant; ****P < 0.0001.